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Summary.-From a multiple-regression analysis of prognostic factors and survival
in a series of 387 patients with primary breast cancer, a prognostic index has been
constructed, based on lymph-node stage, tumour size and pathological grade. This
index is more discriminating than lymph-node stage alone, and enables a larger
group of patients to be identified with a very poor prognosis.
MANY STUDIES of prognostic factors in
breast cancer have been reported in the
literature. In some of these, only one
factor has been studied in isolation. In
others, more than one factor has been
investigated by breaking the data down
into subgroups, each having the same
combination of factors. If more than 3
factors are being studied the number of
possible subgroups becomes large and the
numbers of patients in each subgroup
diminishes correspondingly (Myers et al.,
1966). To overcome this problem some
form of multivariate analysis can be used
to deal with the simultaneous effect of
several factors on prognosis (Myers et al.,
1966; Freedman et al., 1979; Alderson
et al., 1971; Wallgren et al., 1976), and the
multiple regression technique described
by Cox (1972) has been used in a number
of cancer studies (Wilkinson et al., 1979;
Gehen et al., 1976; Palmer et al., 1980;
Lanzottie et al., 1977). It can make use of
all the data from a group of patients
having a wide range of follow-up times,
and is a powerful technique which makes
no assumptions about the form of the
survival curve. It has been used to obtain
the results reported below.
In the Nottingham Breast Cancer
Study, members of a consecutive series of
operable patients have all had a number
of prognostic factors recorded and have
received the same primary treatment. In
1979 we reported preliminary findings in
228 patients who had been followed up for
at least 18 months, and we identified by
use of stage, size and grade, a group of
patients with a very poor prognosis
(Blamey et al., 1979). This paper reports
the next stage in our attempts to combine
factors into a prognostic index.
PATIENTS AND METHODS
The patients for this study were taken from
the first 500 consecutive female patients with
primary operable invasive carcinoma of the
breast seen and treated, under the care of a
single surgeon, by simple mastectomy and
triple-node biopsy at the Nottingham City
Hospital. The prognostic factors selected for
investigation were age, menopausal status
(a premenopausal woman being either still
menstruating or having a plasma sample
containing <50 i.u./I of FSH), tumour size
measured in the fresh mastectomy specimen,
lymph-node involvement judged by histology,
tumour grade, cellular reaction, presence of
sinus histiocytosis in lymph nodes, and
oestrogen-receptor (RE) content of the
primary.
Lymph-node involvement, based on biopsy
of a lower axillary node, an apical axillary
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node and a node from the internal mammary
chain, was classified as:
Stage A: Tumour absent from all 3 nodes
sampled
Stage B: Tumour in low axillary node only
Stage C: Tumour in apical and/or internal
mammary node.
Histological grade (I to III) was deter-
mined by a method based on the criteria of
Bloom & Richardson (1957). Cellular reaction
was scored in 4 categories as described by
Black et al., (1955). The absence or presence
of sinus histiocytosis in lymph nodes was
scored 1 and 2 respectively, whilst cases where
all available lymph nodes were completely
replaced by tumour were scored zero. RE
content was assayed by the method des-
cribed by Maynard & Griffiths (1979) and
tumours were classified as RE+ if they
contained >5 fmol specific oestradiol binding
per mg cytosol protein.
A group of 387 patients for each of whom
all these factors were recorded has been used
for the main analysis. The 113 patients
excluded were accounted for by 69 with no
RE result, 10 with no cell-reaction score, 11
with non-invasive cancer (i.e. intra-duct or
Paget's), and 23 excluded for a variety of
reasons such as previous cancer ofthe breast,
operation not being a simple mastectomy,
inadequate clinical details and no follow-up
at all.
Following the previous work on a prog-
nostic index (Blamey et al., 1979) a decision
was made, after the first 250 patients had
been entered in the main study, that patients
in the poor-prognosis group (Stage C, size
>2 cm, Grade II or III) would be given
adjuvant chemotherapy. This policy con-
tinued until Patient 370 in the main series,
but was discontinued thereafter. Fifteen of
the 387 patients were given adjuvant chemo-
therapy during this period, and it was
necessary to take this into account in the
analysis.
The first patient in the series was treated
just over 6 years before the time of analysis,
the last patient just over 1 year before. With
this length of follow-up available, it was
decided to use survival time as a measure of
the outcome oftreatment.
To assess the relative importance of the
prognostic factors, a series of analyses using
the method due to Cox (1972) has been car-
ried out. The simplest use of the method, as
reported in this paper, assumes a "propor-
tional hazards" model; i.e., that the relative
contribution of each factor to the risk of
dying remains constant over the period
covered. A more detailed analysis (Freedman
& Haybittle, in preparation) using time-
dependent variables has shown that in this
particular set of data there are no significant
departures from such a model.
The Cox method is a multiple regression
technique which allows each variable to be
evaluated independently, taking into account
the effects of all other variables. The coeffi-
cients (/3 values) produced by the analysis
show how much each factor contributes to
the hazard, which is inversely related to
survival. A positive value of : therefore
indicates a poorer survival time as the given
variable increases. Table I shows the coding
used for the various prognostic factors in our
analysis. Survival curves have been cal-
culated using the life-table method with the
time divided into 6-monthly intervals.
RESULTS
These are first presented for the analyses
made onthe group of387 patients in whom
all the factors were recorded. One patient
who died from a road traffic accident
without recurrence 4 months after treat-
TABLE l.-The coding for the various
prognosticfactors
Prognostic factor
Age
Menopausal state
Size
Lymph-node stage
Tumour grade
Cellular reaction
Sinus histiocytosis
Oestrogen receptor (RE)
Adjuvant therapy
Codes used in Cox
analysis
In years
0 =premenopausal
1=postmenopausal
In cm
1=A
2=B
3=C
1=I
2=II
3 =III
1 marked
2=moderate
3 =slight
4=none
0=nodes completely
replaced by tumour
1 =absent
2=present
0 =negative
1 =positive
0 =none
1 =therapy given
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TABLE II.- Values of and Z obtained
when each possible prognostic factor was
included in the Cox analysis
Factor
Age
Menopausal state
Size
Lymph-node stage
Tumour grade
Cell reaction
Sinu. histiocytosis
RE content
Adjuvant therapy
* P<0-01.
** P <0 *001.
-0 0162
0 524
0.172
0-763
0 822
0-091
-0 204
-0- 340
-0-332
z
1 -02
1-50
2.92*
5.29**
4 56**
0-62
1-26
1-72
0-83
Ineit was counted as a withdrawal at the
time of death. All other deaths were
included.
Table II shows the ,B values obtained
when all factors were included in the Cox
analysis. The last column gives the Z
values, which are the ratios ofthe absolute
values of the ,Bs to their standard errors.
If Z > 1-96, p is significantly different
from zero at the 5% level in a two-tailed
test. Stage, size, and grade all fall within
this category. The other coefficients are
not significantly different from zero. This
should not be taken to mean that these
factors have no effect on prognosis, but
only that any effect is too small to be
shown up at the 5% level of significance
with the number of patients in this study.
Adjuvant chemotherapy did not have a
significant effect, though it tended to
reduce the hazard, as shown by the nega-
tive coefficient in Table II. Since this was
applied to a highly selected group (patients
in Stage C with tumours > 2 cm, and in
Grades II and III) its beneficial effect, if
any, in the series will be confined to those
patients, and tend to reduce the gradation
of prognosis with size, stage and grade.
This was borne out by an analysis with
adjuvant therapy excluded, which pro-
duced slightly lower coefficients: 0-169,
0-723 and 0-805 for size, stage and tumour
grade respectively. For the formation of
a prognostic index (see below) it will
therefore be preferable to use the coeffi-
cients obtained from the analysis when
adjuvant therapy was included (viz. those
in Table II).
A prognostic index
The coefficients produced by the Cox
analysis can be used to derive a prognostic
index for each patient (Palmer et al.,
1980). Only the 3 prognostic factors found
to be significant in Table II have been
used, and their coefficients reduced to 2
significant figures. The index (I) for each
patient is then:
I= (0417 x size) + (0.76 x lymph-node
stage) + (0-82 x tumour grade).
The larger the value of I, the worse the
prognosis forthatpatient.
We have investigated the application of
this index in a subset of the data which
excluded the period during which poor-
prognosis patients were treated with
adjuvant therapy. 298 cases, in which all
factors were recorded, were available from
Patients 1-250 and 371-500 in the main
series, and the results presented below
apply to survival in this group. The index
was computed for each patient, and the
patients then arranged in order ofdecreas-
ing values ofI.
FI. 1. Suvia cuve of paiet arane
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FiG. 1. Survival curves of patients arranged
in 3 groups according to index value (whole
lines) compared with survival according to
the 3 stages by lymph-node biopsy (dotted
line).
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We have first compared the performance
of the index with that of lymph-node
stage (the most significant single factor)
alone. The patient group consisted of 154
vStage A, 95 Stage B and 49 Stage C
patients. Fig. 1 shows the survival curves
for these subgroups (dashed lines) together
with those for subgroups containing the
same numbers of patients but selected
according to their I value (viz. the 154
with the lowest values, the 49 with the
highest values and the 95 in between).
It is evident that I gives a better discrim-
ination. The 49 patients with the highest
I value do worse than the 49 Stage C
patients, and the separation between the
best and the worst prognostic groups is
greater.
Our second comparison was with our
earlier criteria for poor prognosis, namely
Stage C, size > 2 cm, Grades II or III.
Twenty-five patients in the group satis-
fied these criteria, and their survival is
compared in Fig. 2 with those of the 65
patients with the highest I values. The
2 curves are almost identical, and the new
index was thus able to identify a larger
group of poor-prognosis patients.
It was also of interest to look at a
group of 64 patients with the lowest I
values. Their survival is also shown in
Fig. 2, and compared with the expected
survival in a normal population of the
same age distribution. It can be seen that
patients with I values < 2-8 constituted a
very good prognosis group.
Lastly we have examined the perform-
ance of the new index as a predictor of
5-year survival. 137 patients were treated
at least 5 years before the assessment
date, and their status at 5 years in the
100
% Survival
50
<2.8 (64)
2.8-4.4 (169)
>4.4 (65)
1 2 3 4 5
Years
FIG. 2. Survival of 64 patients with incdices of
2-8 or less compared with the survival ofan
age-matche(d population free of breast
cancer (.). Survival of 65 patients witl
index > 4 4, compared with the survival of
25 patients identified as lhaving a pooIr
prognosis by a previous index --- -). Also
shown is the survival of 169 patients witl
intermediate indices (2.8-4.4).
3 index ranges used for the graphs of
Fig. 2 are given in Table III.
DISCUSSION
The index derived has selected out 2
groups of patients; 1 with an exceed-
ingly poor prognosis, the other with an
apparently very good prognosis. If the
index is used to predict 5-year disease-free
survival. Table III shows that, of the 51
patients in these two groups, 44 (86%)
have been correctly assigned according
to the index. Nearly two-thirds of the
patients in Table III have intermediate
I values. It may be found after longer
follow-up that a further subdivision of
this group will be valuable in predicting
disease-free survival at 10 years.
Some measure of the extra contribution
ofgrade and stage to prognostic prediction
TABLE III.-Performance of Index in 387 patientsfollowed upfor at least 5 years
Index value
High (>4-4)
Medium (2.8-4.4)
Low (<2.8)
Patient status at 5 years
A
Alive and Alive with
recurrence-free recurrence Dead
(0/) (°h) (%o)
2 (7) 1 (3) 26 (90)
46 (54) 7 (8) 33 (38)
17 (77) 2 (9) 3 (14)
Total
Total
29
86
22
137
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over stage alone can be obtained from the
log likelihood values produced by the Cox
analysis. These give an indication of how
well the model predicts the actual survival,
the greater the log likelihood the better
being the model's performance. The
increase in log likelihood when another
prognostic factor is included shows how
much extra that factor is contributing,
and can be tested for statistical signifi-
cance by comparing twice the increase
with the x2 distribution for one degree of
freedom. The inclusion of grade in addi-
tion to stage alone increases the log
likelihood by 18-8 (P<0.0005). The fur-
ther inclusion of size increases the log
likelihood by 3-7 (P < 0 01).
None ofthe other factors, when included
in the model, significantly increases the
log likelihood. When age, menopausal
status, sinus histiocytosis and RE content
(for all of which the Z values in Table II
were non-significant but greater than 1 0),
were incorporated in theindex, the changes
from the results shown in Figs 1 & 2
and Table III were only marginal.
In the past we have demonstrated RE
content to be a significant prognostic
factor in Stage B and C patients (Bishop
et al., 1979; Blamey et al., 1980). RE is not
a significant factor in the current analysis
because it is strongly correlated with
tumour grade (Maynard et al., 1978;
Elston et al., 1980). When the Cox analysis
was repeated with tumour grade excluded,
the coefficient for RE content was - 0523
and had a significant Z of 2-47. Thus, in
the absence of reliable histopathological
assessment of tumour grade, RE would
give useful prognostic information and
could be used to build an index:
I = (0.18 x size) + (0 68 x stage)
-(052 x RE)
wvhere RE is coded as in Table I.
The day-to-day use of our size, stage
and grade index may be cumbersome
because of the calculation involved. The
factors for stage and grade are similar
and, if these are both made equal to unity
and the multiplying factor for size scaled
up accordingly, we can arrive at a simpler
index of the form:
I = 0-2 x size + stage +grade.
This simpler index gives very similar
results to those obtained with the more
complex formula. For example, the curves
in Fig. 2 are reproduced almost exactly if
the divisions are made at index values of
3 4 and 5 4 instead of at 2-8 and 4-4.
The values of the coefficients found in
our analysis are such that they obtain the
best discrimination on the particular set
of data from which they are derived, since
they give the best fit of the model to the
data. The performance of the index might
be different on another set of data, and
we therefore plan to study its effectiveness
in the patients admitted to the Notting-
ham Breast Cancer Study from Patient
501 onwards.
The estimation of prognosis in the
individual is clearly important for deter-
mining her treatment and follow-up, for
example in making decisions regarding
adjuvant chemotherapy. It is equally
important at the present time in the
evaluation of therapies by controlled
trials, where proper stratification of
patients might be greatly improved by the
application of indices based on a number
of significant factors, each given their
appropriate weight.
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